Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 + Paclitaxel in Cancer with Bone Lesions
NCT02442063Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2015
- Primary completion
- Oct 2016
- Modality
- Radiopharmaceutical
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of radium-223 dichloride in solid tumor and bone metastases, sponsored by Bayer. Primary endpoints: Percentage of participants with thrombocytopenia at Cycle 3 and Percentage of participants with neutropenia at Cycle 3. Started Aug 2015; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
solid tumorbone metastases
Beyond the preview
Go deeper on NCT02442063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442063.